Authors
Nilesh Kapoor, Meng Xu-Welliver, Rina Li Welkie, Amneet Bajwa, Wing Chan, No-Joon Song, Jiasheng Wang, Audrey Sigmund, Yazeed Sawalha, John Reneau, Robert Baiocchi, Beth Christian, Kami Maddocks, David Bond, Zihai Li, Jonathan Brammer, Evandro Bezerra, Samantha Jaglowski, Timothy Voorhees, Marcos de Lima, Austin Sim, Nathan Denlinger
Published in
Clinical lymphoma, myeloma & leukemia. Oct 27, 2026. Epub Oct 27, 2026.
Abstract
Radiation therapy (RT) is a bridging option before chimeric antigen receptor T-cell (CART) infusion in B-cell lymphoma. We evaluated outcomes in patients receiving RT in the 100 days preceding CART infusion, including those who received RT as salvage before leukapheresis.
We retrospectively evaluated 139 patients with aggressive B-cell lymphomas treated with CART from January 2018 to March 2022. Baseline characteristics, response, and toxicities were compared between the RT and non-RT groups. Survival was compared among the RT, systemic-only bridging, and no bridging groups.
Median follow-up was 36 months. Most patients (n = 126, 91%) had diffuse large B-cell lymphoma. Seventy-four (53%) received systemic bridging alone, 13 (9%) received RT alone, and 8 (6%) received both modalities. The RT group (n = 21) had more primary refractory (71% vs. 43%, P = .02) and bulky disease (81% vs. 55%, P = .03). Among evaluable patients, overall response rates were 84% with RT vs. 61% without RT (P = .06). RT patients had less relapse at baseline sites of bulky disease (44% vs. 89%, P = .01), less grade ≥ 3 neutropenia at day +90 (0% vs. 26%, P = .01), but more grade ≥ 3 neurotoxicity (43% vs. 19%, P = .02; adjusted odds ratio 2.87, P = .04). Median progression-free survival (PFS) was longer in RT versus systemic-only bridging (15.8 months vs. 2.9, P = .03). Among patients requiring salvage/bridging therapy, RT was associated with improved overall survival (adjusted hazard ratio 0.35, P < .01).
Radiation before CART was associated with longer PFS, less relapse at sites of bulky disease, and lower hazard of death among patients receiving salvage/bridging therapy.
PMID:
43058005
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0